SBIR/STTR Research Award

Sylvatica I Corps Commercialization Jan High Subzero Equilibrium VCA Cryopreservation

Award identifier fcf10a441a90edc2a162a4308a6b969bba40e0d952a9614f7cd38f59302ae18dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$274,998

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SYLVATICA BIOTECH INC
Proposal award date
2016-04-15
Contract end date
2017-09-30
UEI
FJJVUJGDDLS3
Solicitation number
PA16-414
Topic code
R

Research abstract

DESCRIPTION provided by applicant This program targets the long term preservation of vascularized composite tissues for both autologous and allotransplantation VCA such as of e g muscle flaps digits faces and whole limbs to radically improve restorative and reconstructive medicine We have conceived an integrated two pronged approach in which we will develop new nature inspired and further augmented stasis cocktails optimized for the critical phases of VCA preservation preconditioning and protection prior to storage preservation during storage and revival resuscitation repair after storage as wells as new devices purposefully designed for perfusion storage and evaluation and quality control before transplant decision Our approach is based on using the best strategies employed by freeze tolerant and hibernating animals in nature and then augmenting them with complementary strategies developed through recent scientific understanding bioengineering principles and modern tools Thus our preservation approach is unique and distinct from other approaches since we seek to accomplish storage times of several weeks to months using an unexplored yet highly promising methodology Importantly our approach will not seek to solve all the problems needed for classical cryopreservation approaches but rather be the first to develop preservation in a equilibrium state using high subzero storage temperatures ranging from to C combined with programmed metabolic depression and enhanced stress tolerance pathways These are temperatures and strategies used in nature by many species able to survive months in a state of `suspended animation andapos with the whole animal including every single organ being andquot bankedandquot without injury The technical objective of this Phase proposal is to develop a non toxic multi component next generation cryostasis cocktail and protocol which in Phase will be used for whole mammalian limb preservation with re transplantation We seek to develop a unique holistic and non toxic approach to salvage and preserve human and eventually tissue engineered VCA for unprecedented durations Across three specific aims in this first phase we use skeletal muscle and vascular endothelial cells as a model with the central goal of creating a cocktail and protocol that enables high subzero cryopreservation and the development of a thermodynamically stable state while actively suppressing metabolism and enhancing stress tolerance Several of these sub strategies should also help mitigate ischemia reperfusion injury and in other ways help with rewarming revival and repair post storage This proposal constitutes an important standalone project that should also lead to solutions for preservation of natural and engineered vital organs as well as for traditional cell and tissue banking PUBLIC HEALTH RELEVANCE amputations are conducted each year in the US Almost half are caused by trauma disproportionally affecting young people Furthermore conservative estimates indicate that another Americans suffer life changing facial disfigurement annually The combination of clinical need for vascularized complex allotransplants for these patients and increased surgical capabilities in hand face and limb transplantation results in an ever growing need for vascularized composite tissues At the same time the short current preservation times severely limit the number of these transplants that can be salvaged constrain donor recipient matching and contribute to graft rejection in important ways Our technology promises to overcome these issues by providing banks of vascularized complex allotransplants that can be provided to patients as needed with improved donor recipient matching and graft outcomes

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

19 SBIR/STTR records share this UEI (2015–2024). Reported award amounts total $14,520,595. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.